Antares Pharma buy stratec
Start price
05.02.19
/
50%
€2.77
Target price
04.11.21
€7.58
Performance (%)
18.45%
End price
05.11.21
€3.28
Summary
This prediction ended on 05.11.21 with a price of €3.28. The BUY prediction by stratec finished with a performance of 18.45%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Antares Pharma | - | - | - | - |
| iShares Core DAX® | -0.116% | 1.953% | 14.155% | 16.268% |
| iShares Nasdaq 100 | -2.733% | -1.273% | 31.828% | 43.377% |
| iShares Nikkei 225® | -1.721% | 3.263% | 12.922% | 8.501% |
| iShares S&P 500 | -1.527% | 0.194% | 27.117% | 41.752% |
Comments by stratec for this prediction
In the thread Antares Pharma diskutieren
stratec stimmt der fundamentalen Bewertung mit dem Ergebnis 'überbewertet' nicht zu
Wednesday, the FDA approved Makena. This is a subcutaneous auto-injector to reduce the risk of preterm birth in pregnant women who have previously delivered a preterm baby. It was developed by partner Antares Pharma (ATRS). Janney Montgomery upgrade the stock from Neutral to Buy on this news. Several other analyst chimed in yesterday as well including Jefferies (Buy, $18 price target),
Cowen & Co. (Hold, $20 price target) and B Riley FBR (Hold, $16 price target)
In the thread Trading Antares Pharma
Die von stratec gewählte maximale Laufzeit wurde überschritten